1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Ikaria Inc. - Product Pipeline Review - 2014

Ikaria Inc. - Product Pipeline Review - 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 23 pages

Ikaria Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Ikaria Inc. - Product Pipeline Review - 2014’, provides an overview of the Ikaria Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ikaria Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Ikaria Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Ikaria Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Ikaria Inc.’s pipeline products

Reasons to buy

- Evaluate Ikaria Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Ikaria Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Ikaria Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Ikaria Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ikaria Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Ikaria Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Ikaria Inc. - Product Pipeline Review - 2014
Table of Contents

Ikaria Inc. Snapshot 4
Ikaria Inc. Overview 4
Key Information 4
Key Facts 4
Ikaria Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Ikaria Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Ikaria Inc. - Pipeline Products Glance 9
Ikaria Inc. - Late Stage Pipeline Products 9
Phase III Products/Combination Treatment Modalities 9
Ikaria Inc. - Drug Profiles 10
IK-3001 10
Product Description 10
Mechanism of Action 10
RandD Progress 10
Inomax 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
terlipressin 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Ikaria Inc. - Pipeline Analysis 15
Ikaria Inc. - Pipeline Products by Target 15
Ikaria Inc. - Pipeline Products by Route of Administration 16
Ikaria Inc. - Pipeline Products by Molecule Type 17
Ikaria Inc. - Pipeline Products by Mechanism of Action 18
Ikaria Inc. - Recent Pipeline Updates 19
Ikaria Inc. - Dormant Projects 20
Ikaria Inc. - Locations And Subsidiaries 21
Head Office 21
Other Locations and Subsidiaries 21
Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 23
Disclaimer 23

List of Tables

Ikaria Inc., Key Information 4
Ikaria Inc., Key Facts 4
Ikaria Inc. - Pipeline by Indication, 2014 6
Ikaria Inc. - Pipeline by Stage of Development, 2014 7
Ikaria Inc. - Monotherapy Products in Pipeline, 2014 8
Ikaria Inc. - Phase III, 2014 9
Ikaria Inc. - Pipeline by Target, 2014 15
Ikaria Inc. - Pipeline by Route of Administration, 2014 16
Ikaria Inc. - Pipeline by Molecule Type, 2014 17
Ikaria Inc. - Pipeline Products by Mechanism of Action, 2014 18
Ikaria Inc. - Recent Pipeline Updates, 2014 19
Ikaria Inc. - Dormant Developmental Projects,2014 20
Ikaria Inc., Subsidiaries 21

List of Figures

Ikaria Inc. - Pipeline by Top 10 Indication, 2014 6
Ikaria Inc. - Pipeline by Top 10 Target, 2014 15
Ikaria Inc. - Pipeline by Top 10 Route of Administration, 2014 16
Ikaria Inc. - Pipeline by Top 10 Molecule Type, 2014 17
Ikaria Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 18

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.